What are the characteristics of ADOCIA stock?

ADOCIA is a company operating in the Santé · Biotechnologies · Vaccins et laboratoires de recherche sector. The stock is listed on Euronext Paris under ISIN FR0011184241.

What is the recent price evolution of ADOCIA stock?

Since last close: -3.6 %. Over one week: -3.04 %. Over one year: -54.83 %.

Adocia Confirms Eligibility of Its Shares for PEA-PME

Lyon-based biotech company Adocia, specializing in diabetes and obesity treatments, confirms compliance with all eligibility criteria for the PEA-PME. Its shares can now be fully integrated into accounts benefiting from this tax advantage.

Published on Jun 11, 2026 at 10:56

ADOCIA

4.02 € -3.60 %

Add us as a preferred source on Google

Access to the PEA-PME Tax Advantage

Adocia confirms compliance with the eligibility criteria for the PEA-PME scheme set by Article L.221-32-2 of the Monetary and Financial Code. This scheme offers an income tax exemption on gains, provided that no withdrawals are made during the first five years.

Free · Every morning

Technical market signals, before the opening bell.

Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.

✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

Indicative data. No investment advice. Unsubscribe at any time.

🏢 Other stocks — Santé

🗞️ DBV Technologies stock declines 2%, among the strongest drops on the SBF 120 🗞️ Abivax share price falls below 100 €, symbolic threshold breached 🗞️ Medincell stock breaks its support at €24.10 and slides toward a new low 🗞️ Valneva shares fall 4%, among the worst declines on the SBF 120

Context

Period

Period: 2T2026

Key reported figures

Revenue: 43K€

Guidance from the release

« Au cours de ce trimestre, nous avons continué d’avancer, avec notre partenaire Tonghua Dongbao, vers le dépôt de la demande d’autorisation de mise sur le marché en Chine de BioChaperone® Lispro. »
Le chiffre d'affaires du trimestre, limité à 43 K€, provient d'une étude de faisabilité sur la technologie BioChaperone® pour un partenaire non divulgué. La trésorerie s'établit à 9,7 M€ au 30 juin 2026 contre 17,2 M€ fin 2025. La Société recentre ses priorités sur BioChaperone®, met en pause M1Pram après l'expiration du droit exclusif de négociation de Sanofi et suspend la demande d'essai clinique d'AdoShell®.

Risks mentioned

Horizon de trésorerie limité au début du deuxième trimestre 2027
Trésorerie en baisse à 9,7 M€ au 30 juin 2026 contre 17,2 M€ fin 2025
Expiration du droit exclusif de négociation de Sanofi sur M1Pram et mise en pause du programme
Suspension de la demande d'essai clinique AdoShell® faute de ressources financières et humaines

Opportunities identified

Dépôt en préparation de la demande d'AMM en Chine de BioChaperone® Lispro par Tonghua Dongbao
Paiement d'étape de 20 millions de dollars US conditionné à l'AMM chinoise, plus redevances à deux chiffres
Discussions de prochaines étapes engagées avec deux grandes sociétés pharmaceutiques sur BioChaperone®
Nouvelle plateforme brevetée AdoXLong™ visant une injection mensuelle, protection potentielle jusqu'en 2046
Bons de souscription pouvant générer jusqu'à 10,2 et 11,5 millions d'euros en cas de hausse du cours

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Access to the PEA-PME Tax Advantage

Context

Also read